Department of Medicine
Faculty Profiles by Division

Division of Rheumatology and Clinical Immunology

Faculty Profiles

[Return To Index page]
photo Robyn T. Domsic, MD, MPH


Associate Professor of Medicine


Phone: 412-383-8000

Office: S724 Biomedical Science Tower
3500 Terrace Street
Pittsburgh, PA 15261
Phone: 412-383-8000
Fax: 412-383-8753
Administrative Assistant:
Deborah Pokorney
Address: 3500 Terrace Street
Biomedical Science Tower, South, 7th Floor
Pittsburgh, PA 15261
Phone: 412-383-8123
Fax: 412-383-8753
Education and Training
BS, University of Iowa, 1996
M.D., University of Iowa Carver College of Medicine, 2001
M.P.H., University of Pittsburgh, 2008
Internship, Duke University Medical Center, 2002
Residency, Duke University Medical Center, 2004
Fellowship, University of Pittsburgh Medical Center, 2006
Research Interest
Dr. Domsic's research interest centers around improving the care of patients with scleroderma. Her research to date has focused on creating and testing risk stratification strategies for scleroderma patients. These tools can be used to improve both patient care and clinical trial design. Her second main area of research interest is Raynaud's phenomenon and the vascular manifestations of scleroderma. Specifically she is interested in novel imaging techniques for vascular involvement in scleroderma and assessing new outcome measures for testing therapies treating Raynaud's phenomenon.

Dr. Domsic continues to be actively involved in several multi-center clinical trials investigating potential therapies for the management of scleroderma and Raynaud's phenomenon. She has current funding for an investigator-initiated trial examining the effect of atorvastatin on Raynaud's phenomenon that will be completed only at the University of Pittsburgh.
Clinical Interest
Dr. Domsic's primary clinical focus is the evaluation, management and care of
patients with all types of scleroderma. She is the Clinical Director and sees patients in the Scleroderma Center, which is a multidisciplinary center dedicated to patient care and research of scleroderma. Dr. Domsic is also interested in the evaluation and management of patients with
Raynaud phenomenon and mixed connective tissue disease.

Dr. Domsic and her colleagues in the Scleroderma Center participate in both investigator-initiated NIH and industry-sponsored clinical trials. They believe clinical trials are an important piece to offering advanced treatment options to patients.
For my complete bibliography, Click Here.
Selected Publications:
Gourh, P., Remmers, E. F., Boyden, S. E., Alexander, T., Morgan, N. D., Shah, A. A., Mayes, M. D., Doumatey, A., Bentley, A. R., Shriner, D., Domsic, R. T., Medsger, T. A. Jr, et al. Whole-Exome Sequencing to Identify Rare Variants and Gene Networks that Increase Susceptibility to Scleroderma in African Americans. Arthritis Rheumatol. 2018.
Pauling, J. D., Saketkoo, L. A., Domsic, R. T. Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. Arthritis Rheumatol. 2018; 70(6): 973-974.
Sand, J. M. B., Lamy, P., Juhl, P., Siebuhr, A. S., Iversen, L. V., Nawrocki, A., Larsen, M. R., Domsic, R. T., Franchimont, N., Chavez, J., Karsdal, M. A., Leeming, D. J. Development of a Neo-Epitope Specific Assay for Serological Assessment of Type VII Collagen Turnover and Its Relevance in Fibroproliferative Disorders. Assay Drug Dev Technol. 2018; 16(2): 123-131.
Shah, D. J., Hirpara, R., Poelman, C. L., Woods, A., Hummers, L. K., Wigley, F. M., Wright, J. L., Parekh, A., Steen, V. D., Domsic, R. T., Shah, A. A. Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients with Breast Cancer. Arthritis Care Res (Hoboken). 2018.
Hsu, V. M., Denton, C. P., Domsic, R. T., Furst, D. E., Rischmueller, M., Stanislav, M., Steen, V. D., Distler, J. H. W., Korish, S., Cooper, A., Choi, S., Schafer, P. H., Horan, G., Hough, D. R. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Rheumatol. 2018; 45(3): 405-410.
Pauling, J. D., Domsic, R. T., Saketkoo, L. A., Almeida, C., Withey, J., Jay, H., Frech, T. M., Ingegnoli, F., Dures, E., Robson, J., McHugh, N. J., Herrick, A. L., Matucci-Cerinic, M., Khanna, D., Hewlett, S. A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis. Arthritis Care Res (Hoboken). 2017.
Morgan, N. D., Shah, A. A., Mayes, M. D., Domsic, R. T., Medsger, T. A. Jr., Steen, V. D., Varga, J., Carns, M., Ramos, P. S., Silver, R. M., et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2017; 96(51): e8980.
Pauling, J. D., Frech, T. M., Domsic, R. T., Hudson, M. Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clin Exp Rheumatol. 2017; 106(4): 182-192.
Gordon, J. K., Girish, G., Berrocal, V. J., Zhang, M., Hatzis, C., Assassi, S., Bernstein, E. J., Domsic, R. T., Hant, F. N., Hinchcliff, M., Schiopu, E., Steen, V. D., Frech, T. M., Khanna, D. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. J Rheumatol. 2017; 44(6): 791-794.
Li, G., Larregina, A. T., Domsic, R. T., Stolz, D. B., Medsger, T. A. Jr., Lafyatis, R., Fuschiotti, P. Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. J Invest Dermatol. 2017; 137(5): 1042-1050.
Sponsored Research/Activities
Title: An Open-Label Study of the Apollo Device for Fatigue in Systemic Sclerosis
Role: Principal Investigator
Start Year: 2020
End Year: 2021
Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to evaluate Efficacy, Safety, and Tolerability of JBT-101 is Systemic Lupus Erythematosus
Role: Principal Investigator
Funding Agency: Emory University / National Institute of Arthritis, Muscoskel, & Skin Disease
Grant Number: U19 AI110483
Start Year: 2019
End Year: 2020
Title: Long-term Follow-Up of Participants of the Phase II Study to Evaluate Subcutaneous Abatacept v Placebo in diffuse Cutaneous Systemic Sclerosis-A Double-Blind, Placebo-Controlled, Randomized Trial (ASSET)
Role: Principal Investigator
Funding Agency: University of Michigan/ Bristol Meyers-Squibb
Start Year: 2018
End Year: 2023
Title: Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer
Role: Principal Investigator
Funding Agency: Johns Hopkins University/ National Institute of Arthritis, Muscoskel, & Skin Disease
Grant Number: R01 AR073208
Start Year: 2018
End Year: 2023
Title: Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with mycophenolate to treat scleroderma-related interstitial lung disease (SLS III)
Role: Principal Investigator
Funding Agency: University of California Los Angeles
Grant Number: RES
Start Year: 2018
End Year: 2022
Title: Addressing Critical Knowledge Gaps in Early Diffuse Scleroderma Trial Design
Role: Principal Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: R01 AR069874
Start Year: 2017
End Year: 2020
Title: Translational Studies for Identifying and Targeting Novel Pathways in Systemic Sclerosis Pathogenesis (Clinical Core)
Role: Co-Principal Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: P50 AR060780
Start Year: 2017
End Year: 2022
Title: Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: A Phase I/II Single Center Safety Study
Role: Co-Investigator
Funding Agency: University of Michigan
Grant Number: RES
Start Year: 2017
End Year: 2019